Stay updated on Daratumumab for AML/High-Risk MDS Clinical Trial
Sign up to get notified when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.

Latest updates to the Daratumumab for AML/High-Risk MDS Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedLocations section added, listing Texas (MD Anderson Cancer Center) as a site. The Texas Locations heading and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedMinor site maintenance update: the page now shows Revision: v3.3.2 (replacing v3.3.1) with no changes to study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check38 days agoChange DetectedAdded Revision: v3.3.1 and removed Revision: v3.2.0, signaling a version update that does not modify the trial details or eligibility.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page no longer displays a notice about government funding and operating status; the core trial information remains unchanged.SummaryDifference0.4%

- Check60 days agoChange DetectedThe new screenshot shows minor UI adjustments and wording edits on the study page, while core content (title, NCT number, eligibility criteria, primary/secondary outcomes) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check89 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference3%

Stay in the know with updates to Daratumumab for AML/High-Risk MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.